MENU
+Compare
HYPMY
Stock ticker: OTC
AS OF
Sep 24 closing price
Price
$4.45
Change
-$0.15 (-3.26%)
Capitalization
2.8B

HYPMY stock forecast, quote, news & analysis

Hypera SA is a specialty and generic drug manufacturing company... Show more

HYPMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for HYPMY with price predictions
Sep 24, 2025

HYPMY in -4.57% downward trend, falling for three consecutive days on September 22, 2025

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where HYPMY declined for three days, in of 258 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 71 cases where HYPMY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 15, 2025. You may want to consider a long position or call options on HYPMY as a result. In of 114 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for HYPMY just turned positive on August 25, 2025. Looking at past instances where HYPMY's MACD turned positive, the stock continued to rise in of 60 cases over the following month. The odds of a continued upward trend are .

HYPMY moved above its 50-day moving average on September 23, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for HYPMY crossed bullishly above the 50-day moving average on September 24, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HYPMY advanced for three days, in of 240 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 261 cases where HYPMY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.227) is normal, around the industry mean (17.046). P/E Ratio (19.881) is within average values for comparable stocks, (73.836). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.951). Dividend Yield (0.043) settles around the average of (0.030) among similar stocks. P/S Ratio (2.225) is also within normal values, averaging (46.306).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HYPMY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HYPMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

A.I.Advisor
published Dividends

HYPMY paid dividends on January 12, 2023

Hypera SA HYPMY Stock Dividends
А dividend of $0.06 per share was paid with a record date of January 12, 2023, and an ex-dividend date of December 29, 2022. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Avadel Pharmaceuticals plc (NASDAQ:AVDL), Tilray Brands (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 3.9B. The market cap for tickers in the group ranges from 5.57K to 63.66B. AGN holds the highest valuation in this group at 63.66B. The lowest valued company is BGPPF at 5.57K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was 3%. For the same Industry, the average monthly price growth was 24%, and the average quarterly price growth was 67%. RGTLF experienced the highest price growth at 991%, while ZYBT experienced the biggest fall at -68%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 6%. For the same stocks of the Industry, the average monthly volume growth was -70% and the average quarterly volume growth was 63%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 64
Price Growth Rating: 54
SMR Rating: 82
Profit Risk Rating: 90
Seasonality Score: -23 (-100 ... +100)
View a ticker or compare two or three
HYPMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsGeneric

Profile
Fundamentals
Details
Industry
N/A
Address
Avenida Magalhaes de Castro, 4800
Phone
N/A
Employees
10301
Web
https://www.hypermarcas.com.br